After Sputnik V, Russia now has a second Covid-19 vaccine, says Putin

Russia in August became the first country to grant regulatory approval for a Covid-19 vaccine, doing so before large-scale trials were complete

Vladimir Putin
Vladimir Putin, the President Russia. Photo: Shutterstock
Reuters Moscow
1 min read Last Updated : Oct 14 2020 | 8:05 PM IST
Russia has granted regulatory approval to a second Covid-19 vaccine, a delighted President Vladimir Putin announced at a government meeting on Wednesday.

Putin congratulated scientists for approving the new jab, which was developed by Siberia's Vector Institute and completed early-stage human trials last month.

"We need to increase production of the first and second vaccine," he said in comments broadcast on state TV.

"We are continuing to cooperate with our foreign partners and will promote our vaccine abroad."

Russia in August became the first country to grant regulatory approval for a Covid-19 vaccine, doing so before large-scale trials were complete, to the concern of some in the global scientific community.

About 400 high-risk patients have received that jab, according to the health ministry. The vaccine, called "Sputnik V" in homage to the world's first satellite launched by the Soviet Union, is not yet in general circulation.

Since the start of the pandemic, Russia has recorded 1,340,409 infections, the fourth largest number of cases in the world behind the United States, India and Brazil.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusRussiaCoronavirus Vaccine

Next Story